NCT03087864View on ClinicalTrials.gov

PDL-1 Targeting in Resectable Oesophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions
Esophageal Cancer, Stage IIEsophageal Cancer Stage III
Interventions
DRUG

Atezolizumab

Atezolizumab 1200 mg i.v. day 1-22-43-64-85

DRUG

Carboplatin

Chemotherapy

DRUG

Paclitaxel

Chemotherapy

RADIATION

Radiotherapy 23 x 1.8 Gy

Radiotherapy

Trial Locations (1)

1100 DD

Academic Medical Center, Medical Oncology, Amsterdam

All Listed Sponsors
collaborator

UMC Utrecht

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT03087864 - PDL-1 Targeting in Resectable Oesophageal Cancer | Biotech Hunter | Biotech Hunter